Literature DB >> 12624952

[Gene expression profiles of protein kinases and phosphatases obtained by hybridization with cDNA arrays: molecular portrait of human prostate carcinoma].

Iu P Kniazev1, Iu V Cheburkin, K Spikermann, S Peter, G Jenster, K H Bangma, M I Karelin, M I Shkol'nik, A I Urbanskiĭ, V I Evtushenko, A Ullrich, P G Kniazev.   

Abstract

Hybridization with cDNA arrays was used to obtain expression profiles of 263 protein-tyrosine kinase (PTK), protein-tyrosine phosphatase (PTP), dual-specific phosphatase (DuSP), and other genes for the normal prostate tissue, primary prostate carcinomas (PC) of 84 patients, 7 xenografts, and 5 carcinoma cell lines. Analysis of 96 profiles revealed eight clusters of genes coexpressed in PC (coefficient of correlation r > 0.7). According to the known functions of their genes, the clusters were designated as proliferating-cell (CDC42, TOP2A, FGFR3, MYC, etc.), neoangiogenesis and blood-cell (LCK, VAV1, KDR, VEGF, MMP9, SYK, PTPRS, and FLT4), invasion-1 and invasion-2 (ADAM17, TRPM2, DUSP6, VIM, CAV1, CAV2, JAK1, PTPNS1, FYN, and PDGFB), HER2, and PSA/PSM/HER3. Basing on expression profiles of 66 genes, a molecular classification of PC was constructed and allowed discrimination between PC and cell lines or xenografts at 98.9% probability. The results suggested that, along with PSA, PSM (FOLH1), kallikrein-2, and a-2-macroglobulin, cell signaling genes EGFR, HER2, HER3, TOP2, KRT8, KRT18, VEGF, CD44, VIM, CAV1, and CAV2 may serve as diagnostic and prognostic markers in PC. The HER2, VEGF, and CD44 genes and the MMP and ADAM families were assumed to be promising targets for inhibitors of PC cell proliferation and metastasis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12624952

Source DB:  PubMed          Journal:  Mol Biol (Mosk)        ISSN: 0026-8984


  7 in total

Review 1.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

2.  Genomic profiling of tumor initiating prostatospheres.

Authors:  Maria Ana Duhagon; Elaine M Hurt; Jose R Sotelo-Silveira; Xiaohu Zhang; William L Farrar
Journal:  BMC Genomics       Date:  2010-05-25       Impact factor: 3.969

3.  Characterization of kinase gene expression and splicing profile in prostate cancer with RNA-Seq data.

Authors:  Huijuan Feng; Tingting Li; Xuegong Zhang
Journal:  BMC Genomics       Date:  2018-08-13       Impact factor: 3.969

4.  Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice.

Authors:  Yaser Salaymeh; Marganit Farago; Shulamit Sebban; Batel Shalom; Eli Pikarsky; Shulamit Katzav
Journal:  Life Sci Alliance       Date:  2020-04-10

5.  Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo.

Authors:  Anna Goc; Belal Al-Husein; Katerina Katsanevas; Alison Steinbach; Uvette Lou; Harika Sabbineni; David L DeRemer; Payaningal R Somanath
Journal:  Oncotarget       Date:  2014-02-15

6.  Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes.

Authors:  Batel Shalom; Marganit Farago; Eli Pikarsky; Shulamit Katzav
Journal:  Oncogenesis       Date:  2018-10-08       Impact factor: 7.485

7.  Vav1 Promotes B-Cell Lymphoma Development.

Authors:  Batel Shalom; Marganit Farago; Yaser Salaymeh; Shulamit Sebban; Eli Pikarsky; Shulamit Katzav
Journal:  Cells       Date:  2022-03-10       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.